Metformin and Iodinated Contrast CT: When Should You Stop and Restart It?

Core answer: The word “CT” alone does not determine whether metformin should be stopped. Confirm whether the scan uses no contrast, intravenous iodinated contrast, or an intra-arterial catheter procedure, and check the recent eGFR and whether acute kidney injury is present. Some Korean product labels direct patients to stop metformin before or at an iodinated-contrast study, wait at least 48 hours and restart only after kidney function is stable. The American College of Radiology (ACR), however, says that patients without acute kidney injury and with eGFR at least 30 mL/min/1.73 m² do not need to stop metformin for intravenous iodinated contrast. Because product labels and institutional protocols differ, follow the imaging center and prescriber’s written instructions. Do not restart automatically just because 48 hours have passed if a kidney test was requested.

Who does this answer apply to?

This is general information for adults taking metformin alone or in a combination diabetes tablet who are scheduled for CT, angiography or a catheter procedure involving contrast. Check the ingredient list for “metformin,” because the brand name may not make it obvious.

A separate plan is needed for dialysis, eGFR below 30, recent or suspected acute kidney injury, reduced urine output, severe dehydration or infection, worsening heart failure, liver disease, pregnancy or an emergency study. This page cannot determine an individual stop or restart time.

First identify the type of imaging study

  • Noncontrast CT: if no iodinated contrast is injected, the contrast-related metformin issue does not apply.
  • Intravenous iodinated contrast CT: contrast is usually injected into a vein in the arm. Recommendations depend on kidney function, acute illness and the policy being followed.
  • Intra-arterial contrast study: angiography or cardiac catheterization may use a more cautious rule because of the pattern of kidney exposure and possible renal artery embolic risk.
  • Gadolinium contrast for MRI: this is not iodinated CT contrast. ACR says metformin does not need to be stopped for a usual gadolinium dose, although kidney function can affect whether the MRI contrast itself is appropriate.

If the appointment only says “contrast scan,” ask for the contrast type and route.

Why is metformin sometimes withheld?

Metformin itself does not make patients more likely to develop post-contrast acute kidney injury. The concern is that if acute kidney injury occurs around the study, metformin can accumulate and increase the risk of rare but life-threatening metformin-associated lactic acidosis.

ACR notes that lactic acidosis after intravenous iodinated contrast has not been reported in patients properly selected to receive metformin. This is why some radiology guidelines avoid unnecessary interruption while drug labels and some institutions use a more cautious rule.

What do Korean product labels say?

Korean MFDS product information for metformin products can direct patients to discontinue the medicine before or at the start of an iodinated-contrast examination, withhold it for at least 48 hours, and restart only after kidney function has been reassessed and is stable or no further injury risk is found.

Combination tablets containing metformin may carry the same warning. Korean hospital protocols can therefore be more restrictive than ACR guidance. Do not override local instructions using a foreign guideline.

How does ACR guidance differ?

ACR divides patients into two broad categories.

  • No acute kidney injury and eGFR at least 30, intravenous iodinated contrast: metformin does not need to be stopped before or after the study, and a postprocedure kidney test is not obligatory for everyone.
  • Acute kidney injury, eGFR below 30, or an arterial catheter study that may cause renal artery emboli: stop metformin before or at the procedure, withhold it for 48 hours, and restart only after kidney function has been reevaluated and found to be normal or stable.

U.S. FDA-style DailyMed labeling is more restrictive than ACR. It directs withholding for eGFR 30–60, a history of liver disease, alcoholism or heart failure, or intra-arterial iodinated contrast, followed by an eGFR check 48 hours later and restart only if kidney function is stable.

Different instructions reflect different scopes and risk thresholds. They do not mean a patient should choose whichever rule is more convenient.

Five questions to settle before the appointment

  1. Exact medicine: Is metformin taken alone or in a combination tablet, and is it immediate-release or extended-release?
  2. Exact study: Is this noncontrast CT, intravenous iodinated-contrast CT, intra-arterial angiography or MRI?
  3. Recent kidney function: What are the creatinine date and eGFR? Is a newer test needed because health status has changed?
  4. Acute risk factors: Report recent vomiting, diarrhea, fever, poor intake, reduced urine, severe infection or worsening heart failure.
  5. Stop and restart plan: Confirm the last dose, whether a postprocedure kidney test is required, the exact restart instruction and the glucose plan while metformin is held.

What should you do on the day?

Follow the specific instruction from the imaging center, such as “hold the morning dose” or “continue through the study.” Do not stop for several days on the basis of an internet article. If metformin was taken despite an instruction to hold it, tell the radiology team the product, dose and time. Do not conceal it or cancel an urgent study on your own.

Avoiding dehydration may matter when fluids are permitted, but a person with heart failure, dialysis or a fluid restriction should not follow generic advice to drink large amounts. Clarify fasting, permitted fluids and other medicines with the imaging center.

Can you restart automatically after 48 hours?

No. Forty-eight hours is a reassessment point in several protocols, not an automatic restart time for every patient. If a creatinine or eGFR check was ordered, wait for confirmation that kidney function is stable. Acute kidney injury, reduced urine, dehydration, ongoing vomiting or diarrhea, or worsening heart failure can delay restart.

Do not double a dose to replace tablets that were held. Ask how often to check glucose and who to contact if readings rise. Do not add another person’s diabetes medicine or change insulin without a plan.

What to record after the study

  • study date, contrast name and intravenous or intra-arterial route
  • last metformin dose and the instructed restart date
  • pre- and postprocedure creatinine and eGFR when tested
  • urine output, vomiting, diarrhea, intake, swelling or breathlessness
  • glucose readings and symptoms such as severe thirst, frequent urination, vomiting or confusion

Contact the clinical team if vomiting or diarrhea persists, fluids cannot be kept down, urine output falls noticeably, or new swelling or breathlessness occurs.

Warning signs of lactic acidosis

Metformin-associated lactic acidosis is rare but is a medical emergency. Obtain urgent medical help for:

  • unusual severe weakness or muscle pain
  • deep or rapid breathing, or shortness of breath
  • marked sleepiness, confusion or difficulty waking
  • unexplained abdominal pain, nausea, vomiting or diarrhea
  • severe dizziness or feeling unusually cold
  • a slow or irregular heartbeat, or fainting

An allergic contrast reaction is a different problem. Hives, swelling of the face, tongue or throat, breathing difficulty or fainting during or soon after the study needs immediate help from radiology staff or emergency services.

Korean and international practice

In Korea, use the MFDS labeling for the dispensed product together with the imaging center and prescriber’s protocol. A 2020 Korean Diabetes Association and Korean Society of Nephrology consensus advised holding metformin on the day of intravenous iodinated contrast through 48 hours afterward when eGFR is below 60, and holding it for intra-arterial administration, with restart after kidney function has not declined.

ACR uses a less restrictive threshold for intravenous contrast: no acute kidney injury and eGFR at least 30 generally does not require interruption. When imaging is performed abroad, follow the local service but share the study and restart plan with the clinician managing diabetes.

Questions for the imaging center or prescriber

  • Will this study use intravenous or intra-arterial iodinated contrast?
  • Does my recent eGFR require metformin to be held?
  • When is my last dose, and exactly when may I restart?
  • Do I need creatinine or eGFR testing 48 hours afterward?
  • How often should I check glucose while metformin is withheld?
  • Can the other ingredient in my combination tablet be continued?

Related reading

Sources

Reviewed: October 31, 2026. General health information only. It does not replace an individual metformin stop or restart instruction, contrast decision, fluid plan or diabetes treatment plan. No separate clinician review is claimed.